Co-ablation of lung malignancies with coexisting usual interstitial pneumonia: a retrospective analysis of safety and efficacy.

PURPOSE: This retrospective study aimed to evaluate the feasibility and safety of co-ablation (Co-A) for lung malignancies in patients with usual interstitial pneumonia (UIP).

MATERIALS AND

METHODS

We retrospectively reviewed the clinical records of 1,537 consecutive patients treated for malignant lung tumors. UIP was assessed using standard-dose computed tomography (CT). Overall, 14 patients (12 men and two women; mean age ± standard deviation: 71.68 ± 7.83 years, range: 60-87 years) with UIP underwent CT-guided percutaneous Co-A. The mean tumor size was 29.14 mm (standard deviation: 12.60; range: 12-45 mm). Follow-up was performed using CT 1 and 3 months after Co-A. Complications and safety outcomes were also assessed.

RESULTS

The median follow-up duration for all patients was 3 months (range: 1-5 months). The mortality rate was 0% within 30 d of ablation. Major complications, including pneumonia and bronchopleural fistula, occurred in 14.3% (2/14) of patients. The technical success rate was 100%.

CONCLUSION

Co-A appears to be a safe and effective treatment for lung malignancies in patients with UIP.